Regarding the prognostic value of TET1 and TET2 in AML patients, our results could not confirm that TET1 and TET2 overexpression were a bad prognostic factor for AML, as we were not able to find a significant association between TET1 or TET2 expression and survival rates (DFS and OS) of the patients. The gene discussed is TET1; the disease is acute myeloid leukemia.